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Howard L. West, MD,* and David H. Garfield, MD†
In this issue, Cadranel et al.1 on behalf of the Intergroupe Francophone de Cance´rologieThoracique (IFCT) describe their experience of administering the epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib as single-agent, first-line
treatment to 88 patients with advanced bronchioloalveolar carcinoma (BAC) or adeno-
carcinoma with BAC features (IFCT-0401). Similar to other studies in this setting,2,3 the
authors note its significant activity, but this work also highlights in a clinical report the
highly clinically relevant variable of BAC subtype.
Mucinous BAC (M BAC) arises from mucinous metaplasia of bronchiolar cells and
demonstrates strong intra- and extracellular mucosecretion.4,5 This form is more often
associated with aerogenous spread, advanced disease, bronchorrhea, and a relatively rapid
disease course.4 In contrast, nonmucinous BAC (NM BAC) can arise from either of two
similar terminal cell types that are often detected in the same tumor: Clara cells and type
II pneumocytes. NM BAC is most often detected at an early and resectable stage, is
typically asymptomatic for a prolonged period, and its course is more likely to be
indolent.6 Although the NM BAC subtype is generally noted to be more common and
represent 50 to 60% of cases compared with about 30 to 40% with M BAC and the
remainder to be mixed,7–9 the IFCT trial by Cadranel notes an even split between the two
subtypes in unresectable disease.
In addition to distinctive cells of origin and natural histories, there is an emerging
body of data that illustrates specific molecular profiles that correlate with very different
responses to our common systemic therapies. Diastase resistant periodic acid Schiff stains
M BAC essentially uniformly but is seen in only a small minority of NM BAC tumors.10
In contrast, thyroid transcription factor-1 is expressed consistently in lung adenocarcino-
mas with terminal respiratory unit morphology11 and is nearly uniformly expressed in NM
BAC tumors but is uncommon in patients with M BAC.6 EGFR activating mutations,
consistently associated with profound and prolonged responses to EGFR TKIs, have been
seen in anywhere from 19 to 88% of patients with NM BAC tumors but have only been
very rarely been reported in cases with M BAC (reviewed in Ref. 12). In contrast,
V-Ki-ra2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, seen in the
great majority of M BAC cases TKI,13,14 are associated with a very low likelihood of a
radiographic response to an EGFR.
The EGFR TKIs are commonly used as an early treatment for patients with
unresectable BAC, but the current limited evidence strongly supports recognition of the
distinction between the two major BAC subtypes, in accordance with the molecular
features described earlier. The IFCT-0401 trial reported here demonstrates a significantly
higher disease control rate with gefitinib among those patients with NM BAC. In fact, no
responses to an EGFR TKI have been reported in the literature for any patient with M
BAC, as favorable results with this line of treatment seem limited to patients with NM
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BAC histology.6 The results of the IFCT study support this
conclusion, with a median progression-free survival of 11.4
versus 2.6 months with gefitinib for patients with NM and M
BAC, respectively (p  0.0024).
Although chemotherapy has not been as well studied in
prospectively designed studies of advanced BAC, the limited
available evidence suggests that the distinction between BAC
subtypes may be relevant here as well. Responses to a
96-hour infusion of paclitaxel were seen only among patients
with M BAC in the Southwest Oncology Group (SWOG)
9714 trial, although the number of patients with central
review of pathology specimens was small.15 A study of
pemetrexed in advanced BAC, SWOG 0326, has recently
been completed, but results have not yet been reported, and it
will be important to assess whether differences in outcomes are
observed between M and NM BAC subtypes. Interestingly,
there has been an anecdotal report of two cases of BAC, one M
BAC and the other NM BAC, treated with pemetrexed and
having durable responses.16
Despite the converging evidence supporting the clinical
relevance of making a distinction between major BAC sub-
types, this information is unfortunately not consistently col-
lected or reported in trials of patients with either resected or
advanced BAC. Importantly, the collection and reporting of
this information should optimally be predicated on pathologic
interpretation of histologic rather than cytologic specimens.
In fact, consensus recommendations from the First Interna-
tional Association for the Study of Lung Cancer (IASLC)/
American Society for Clinical Oncology (ASCO) Consensus
Conference on Bronchioloalveolar Carcinoma clearly state
the need for a histologic specimen and the need for a precise
histologic diagnosis.17 Reflecting this, many trials for this
population require a histologic diagnosis and central review
of BAC tumors. Thus, it is a shortcoming of the IFCT trial
that either cytologic or histologic diagnosis was considered
adequate for patient entry as long as there was a diffuse or
pneumonic-type radiologic presentation suggestive of adeno-
carcinoma with BAC features.
Given the infrequency of BAC (5%), even when
pooled by subtype, it is likely infeasible to run prospective
trials restricted to a particular BAC subhistology. Neverthe-
less, the data on the relevance of this distinction have been so
consistent and so clinically significant that we must acknowl-
edge that we need to identify and document BAC subhistol-
ogy. To do less is to consign ourselves to an unacceptable risk
of obscuring important observations and thereby treat many
patients with BAC suboptimally.
The overall management of non-small cell lung cancer
is moving into a new era in which we are achieving higher
response rates and long survival by refining our treatment
recommendations according to histologic and molecular fea-
tures of each patient’s tumor. This strategy is predicated on
detailed pathologic review and reporting of results by histo-
logic subtype, as we move toward a greater understanding of
the distinct clinical behaviors and responses to systemic
therapies. Without the ability to discriminate detailed histo-
logic data, results of trials focusing on patients with BAC
and/or adenocarcinoma with BAC features will be obscured
by results pooled between heterogeneous populations.
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